Actively Recruiting
Led by Tongji Hospital · Updated on 2026-04-08
118
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research aims to evaluate the combined use of tegileridine patient-controlled intravenous analgesia (PCIA) and intercostal nerve block (ICNB) after thoracoscopic lung resection. The study explores whether this combination provides early and stable pain relief, supports rapid recovery, and may reduce chronic post-surgical pain. It focuses on patients undergoing lobectomy or segmentectomy for lung conditions. Participants receive either sufentanil or tegileridine intravenously 40 minutes before surgery ends, followed by PCIA. Both groups also undergo intercostal nerve block with ropivacaine injected into specific intercostal spaces. Sufentanil dosing is 0.15 µg/kg (up to 10 µg), while tegileridine is dosed at 0.015 mg/kg (up to 1 mg), with detailed PCIA pump settings for both drugs. During the study, researchers monitor pain levels using the Visual Analog Scale over 48 hours postoperatively, along with total rescue analgesic use, PCIA parameters, opioid-related side effects, hospital stay length, sleep quality, rescue analgesic interventions, and overall patient satisfaction up to 10 days. The trial is randomized and triple-masked, aiming to assess the analgesic effectiveness and safety of the combined treatments.
CONDITIONS
Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Surgery day and immediate post-operative period
Participants undergo thoracoscopic lung resection surgery with intercostal nerve block administered before closing the chest. Tegileridine or sufentanil is given intravenously 40 minutes before the end of surgery, followed by patient-controlled intravenous analgesia (PCIA).
1 visit for surgery and analgesic intervention
Duration - 48 hours
Participants receive continuous analgesic treatment via patient-controlled intravenous analgesia (PCIA) for pain management after surgery.
Continuous treatment over 48 hours with monitoring visits
Duration - Up to 10 days
Participants are monitored for pain scores, opioid-related adverse events, quality of sleep, rescue analgesic interventions, and overall satisfaction during recovery after surgery.
Follow-up visits over 10 days
Total: 1 location
1
Tongji hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
A
Aijun Xu, Dr.
H
Hongbo Zheng, Dr.
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hongbo Zheng, Ruochen Pan, Fan Yuan...
https://pubmed.ncbi.nlm.nih.gov/42082224